Study
| Open-label, phase 3 trial |
| Stage IB to IIIA resectable NSCLC |
| Three cycles neoadjuvant treatment |
| Nivolumab plus platinum-based chemotherapy (n=176) or platinum-based chemotherapy (n=176) |
Efficacy
| mEFS: 31.6 m vs 20.8 m (HR:0.63; 97.38% CI, 0.43 to 0.91; P=0.005) |
| pCR: 24.0% vs 2.2% (OR:13.94; 99% CI, 3.49 to 55.75; P<0.001) |
| mOS: NR vs NR (HR: 0.57; 99.67% CI, 0.30 to 1.07; P=0.008) |
Safety
| Grade >= 3 AEs: 33.5% vs 36.9% |
| Grade >=3 AEs neutropenia:8.5% vs 11.9% |
| Discontinuation of treatment 10.2% vs 9.7% |
N Engl J Med 2022; 386:1973-1985
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
http://doi.org/10.1056/NEJMoa2202170
Reviewed by Hasan Cagri Yildirim, MD on Sep 20, 2022
